Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/11493
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorAghamohammadi, Asghar-
dc.contributor.authorAbolhassani, Hassan-
dc.contributor.authorKutukculer, Necil-
dc.contributor.authorWassilak, Steve-
dc.contributor.authorPallansch, Mark-
dc.contributor.authorKluglein, Samantha-
dc.contributor.authorQuinn, Jessica-
dc.contributor.authorSutter, Roland-
dc.contributor.authorWang, Xiaochuan-
dc.contributor.authorSanal, Ozden-
dc.contributor.authorLatysheva, Tatiana-
dc.contributor.authorIkinciogullari, Aydan-
dc.contributor.authorBernatowska, Ewa-
dc.contributor.authorTuzankina, Irina-
dc.contributor.authorCosta Carvalho, Beatriz-
dc.contributor.authorFranco Restrepo, José Luis-
dc.contributor.authorSomech, Raz-
dc.contributor.authorKarakoc Aydiner, Elif-
dc.contributor.authorSingh, Surjit-
dc.contributor.authorBezrodnik, Liliana-
dc.contributor.authorEspinosa Rosales, Francisco-
dc.contributor.authorShcherbina, Anna-
dc.contributor.authorLung Lau, Yu-
dc.contributor.authorNonoyama, Shigeaki-
dc.contributor.authorModell, Fred-
dc.contributor.authorModell, Vicki-
dc.contributor.authorRidha Barbouche, Mohamed-
dc.contributor.authorMcKinlay, Mark-
dc.date.accessioned2019-07-23T16:56:45Z-
dc.date.available2019-07-23T16:56:45Z-
dc.date.issued2017-
dc.identifier.citationAghamohammadi A, Abolhassani H, Kutukculer N, Wassilak SG, Pallansch MA, Kluglein S, Quinn J, Sutter RW, Wang X, Sanal O, Latysheva T, Ikinciogullari A, Bernatowska E, Tuzankina IA, Costa-Carvalho BT, Franco JL, Somech R, Karakoc-Aydiner E, Singh S, Bezrodnik L, Espinosa-Rosales FJ, Shcherbina A, Lau YL, Nonoyama S, Modell F, Modell V; JMF Centers Network Investigators and Study Collaborators, Barbouche MR, McKinlay MA. Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication. Front Immunol. 2017 Jun 13;8:685.spa
dc.identifier.issn1664-3224-
dc.identifier.urihttp://hdl.handle.net/10495/11493-
dc.description.abstractABSTARCT: Immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) have been isolated from primary immunodeficiency (PID) patients exposed to oral poliovirus vaccine (OPV). Patients may excrete poliovirus strains for months or years; the excreted viruses are frequently highly divergent from the parental OPV and have been shown to be as neurovirulent as wild virus. Thus, these patients represent a potential reservoir for transmission of neurovirulent polioviruses in the post-eradication era. In support of WHO recommendations to better estimate the prevalence of poliovirus excreters among PIDs and characterize genetic evolution of these strains, 635 patients including 570 with primary antibody deficiencies and 65 combined immunodeficiencies were studied from 13 OPV-using countries. Two stool samples were collected over 4 days, tested for enterovirus, and the poliovirus positive samples were sequenced. Thirteen patients (2%) excreted polioviruses, most for less than 2 months following identification of infection. Five (0.8%) were classified as iVDPVs (only in combined immunodeficiencies and mostly poliovirus serotype 2). Non-polio enteroviruses were detected in 30 patients (4.7%). Patients with combined immunodeficiencies had increased risk of delayed poliovirus clearance compared to primary antibody deficiencies. Usually, iVDPV was detected in subjects with combined immunodeficiencies in a short period of time after OPV exposure, most for less than 6 months. Surveillance for poliovirus excretion among PID patients should be reinforced until polio eradication is certified and the use of OPV is stopped. Survival rates among PID patients are improving in lower and middle income countries, and iVDPV excreters are identified more frequently. Antivirals or enhanced immunotherapies presently in development represent the only potential means to manage the treatment of prolonged excreters and the risk they present to the polio endgame. Keywords: Poliovirus eradication, Immunodeficiency-associated vaccine-derived polioviruses, Oral poliovirus vaccine, Humoral immunodeficiency, Combined immunodeficiency, Primary immunodeficiencyspa
dc.format.extent9spa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherFrontiers Research Foundationspa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsAtribución 2.5*
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by/2.5/co/*
dc.subjectPoliovirus derivados de vacuna-
dc.subjectPoliovirus oral-
dc.subjectVacuna antipoliomielítica oral-
dc.subjectInmunodeficiencia humoral-
dc.subjectInmunodeficiencia combinada-
dc.subjectInmunodeficiencia primaria-
dc.titlePatients with primary immunodeficiencies are a reservoir of poliovirus and a risk to polio eradicationspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupInmunodeficiencias Primariasspa
dc.identifier.doi10.3389/fimmu.2017.00685-
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
oaire.citationtitleFrontiers in Immunologyspa
oaire.citationstartpage1spa
oaire.citationendpage10spa
oaire.citationvolume8spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by/4.0/spa
dc.publisher.placeSuizaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTspa
dc.type.localArtículo de investigaciónspa
dc.description.researchgroupidCOL0012426spa
dc.relation.ispartofjournalabbrevFront Immunolspa
Aparece en las colecciones: Artículos de Revista en Ciencias Médicas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
AghamohammadiAsghar_2017_PatientsPrimaryImmunodeficiencies.pdfArtículo de investigación368.85 kBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons